Alfred Alfred Nijkerk Pharm.D.


Alfred holds a MSc in Pharmacy and a PharmD from Utrecht University. Starting as an Industrial Pharmacist, he founded several pharmaceutical contract manufacturing companies before founding VenGen, a hands-on investors and life sciences start-up management company, in 2001. Since then VenGen co-founded several life science ventures, amongst which FlexGen, DiagnOptics and to-BBB technologies. Alfred was to-BBB's Chief Business Officer from founding until January 1st, 2008.



Farid Farid El Oualid Ph.D.


Farid El Oualid received his PhD in Bioorganic Chemistry in 2005 from Leiden University. After his PhD, Farid performed post-doctoral research at Oxford University and it was during this period that he started getting interested in the emerging Ubiquitin Proteasome Field. In 2008 he joined the Netherlands Cancer Institute where he focused on the development of chemical technologies for ubiquitin(-like protein) based research tools. Based on this, he co-founded UbiQ in 2010 where he is responsible for general lab management and product development.




Alessia Amore Ph.D.

senior scientist



Alessia has received her doctorate in synthetic organic chemistry (2006) from the University of Amsterdam in the group of Prof. Henk Hiemstra. In 2009, after a few years of research in bio-organic (at the VU in Amsterdam, as a Postdoc) and medicinal chemistry (at Dompè, a pharmaceutical company, in Italy), she joined the Chemical Biology group of Prof. Huib Ovaa at the NKI working on projects that merge different branches of science, and to apply chemistry for technology development. She obtained a IEF Marie Curie Fellowship to work on the total synthesis of a MHC class I platform. Besides the research on the MHC platform, she worked on the design and the synthesis of new small drug-like molecules with the aim to discover new drug targets. Since summer 2015, Alessia entered the ubiquitin field by joining UbiQ.





Oana Onciu MSc


Oana obtained her Pharmacist degree in Bucharest, at the Carol Davila University of Medicine and Pharmacy. After working as a pharmacist and pharmacy manager for three years, Oana pursued a research master in Pharmaceutical Sciences at Utrecht University and decided to enroll in early drug discovery. Oana joined UbiQ as an intern in early 2016, and continued working at UbiQ as a scientist. She furthermore joined our subsidiary company SumiQ in January 2017. Oana is part of the SumiQ team responsible for biochemical assays development and medium throughput compound screening.

   Rianne van der Pijl

Rianne van der Pijl


Rianne received her master’s degree in Biopharmaceutical Science from the University of Leiden in 2012. After this she spent a few years as a researcher in the neuroscience field. Mid 2017 she started working for UbiQ as a scientist. She is part of the team responsible for developing biochemical assays and medium throughput compound screening.



UbiQ was founded by Farid El Oualid and Huib Ovaa, two distinguished scientists from the Netherlands Cancer Institute, together with Alfred Nijkerk, an experienced biotech entrepreneur. 


Founders Huib Ovaa PhD


Since 2004 Huib leads a research team specialized in organic synthesis, chemical biology and drug innovation. Huib Ovaa is a professor of chemical biology of post translational protein modifications at the faculty of mathematics and natural sciences of Leiden University.